The placement of a permanent pacemaker is the definitive treatment for sinus node dysfunction, but not everyone needs this.
The singer had to cancel tour dates after blowing out his eardrum, and he says the hardest part hasn’t been the pain — it’s ...
Sanofi & Regeneron’s Dupixent pivotal study meets all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis: Paris Monday, November 10, ...
ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Phase ...
This article deconstructs the IIH guidelines, contrasting medical management (acetazolamide, topiramate) with the practical ...
A terminally ill man is preparing to marry the love of his life next month as he enters palliative care. Daniel Singleton was ...
Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, nasal congestion and nasal polyps in patients aged 6 years ...
Dupixent sBLA accepted for priority review by the US FDA with a target action date of February 28, 2026; if approved, Dupixent would be the first and only medicine indicated specifically for AFRS, ...
Putin met with a representative of Poland's official National Health Program to discuss the possibility of banning the sale ...
When Mrs L, a 52-year-old teacher, first walked into my clinic, her face told a story of exhaustion and fear. She had been ...